Kyverna Therapeutics Inc. Live Stock Price Today, Share Analysis and Chart

Name: Kyverna Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Kyverna Therapeutics Inc.
Rating: 2.07583325
Author: Trendlyne DVM scores

about

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made...

4.15 0.13 (3.23%)

43.77% Fall from 52W High

286.3K

XNAS Volume

XNAS 11 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

13.3 / 100

Technically Moderately Bullish

69.7 / 100

No estimates available

Kyverna Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Kyverna Therapeutics Inc. Live Stock Price Today, Share Analysis and Chart

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made...

43.77% Fall from 52W High

SWOT Analysis

Kyverna Therapeutics Inc Live Price Chart